A psychedelics R&D biotech company, known for providing novel treatments for addictions, is opening a new ketamine clinic

Awakn Life Sciences Corp. (OTCQB: AWKNF) just signed a five-year lease in Oslo as part of the company’s Nordic expansion plans.

Awakn’s new Norwegian premises will be larger than the existing one, which it will replace.

See Also: Exclusive – New Latin American JV To Provide More Psychedelic Medical Treatments For Mental Health Conditions

The new six-treatment room clinic, located close to Oslo's center, will have an increased capacity for treating clients and potentially act as a research and clinical trials …

Full story available on Benzinga.com